Inebilizumab, Viela Bio’s orphan drug for treating the rare neuroinflammatory autoimmune disease, neuromyelitis optica spectrum disorder (NMOSD), is among the latest batch of products that the European Medicines Agency is starting to review for pan-EU approval.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?